Sriram Rathi

Sriram Rathi, pharma analyst at Anand Rathi is of the view that one may pick Cipla and Dr Reddys Laboratories from largecap pharma space.

Sell Ranbaxy Laboratories: Sriram Rathi

Sriram Rathi, pharma analyst at Anand Rath recommends selling Ranbaxy Laboratories with a target of Rs 375.

Checkout: Anand Rathi's bets in pharma space

Sriram Rathi recommends buying Cipla and Dr Reddys Laboratories among largecaps and Indoco Remedies and Netco Pharma among midcaps.

Ranbaxy Laboratories may test Rs 375: Sriram Rathi

According to Sriram Rathi of Anand Rathi, one may buy Ranbaxy Laboratories with a long term perspective.

Sriram Rathi positive on Dr Reddys Laboratories

Sriram Rathi of Anand Rathi is positive on Dr Reddys Laboratories. "We are expecting strong results to continue for the company for the next 2-4 quarters," he adds.

Glenmark Pharma may touch Rs 658, says Sriram Rathi

Sriram Rathi of Anand Rathi is positive on Glenmark Pharma with a target of Rs 658.

Ranbaxy to drag; buy DRL, Glenmark; neutral on Lupin: Rathi

He is positive on Dr Reddy mainly because the company is going to benefit significantly in FY14 and FY15 from the new launches and at the same time the margins will also be higher. He does not expect any major surprise coming in Lupins' quarterly result.

Book profits in Lupin, hold Sun Pharma: Sriram Rathi

According to Sriram Rathi of Anand Rathi, one can book profits in Lupin at current valuations. He advised holding Sun Pharma as he has neutral rating on teh stock.

Hold Wockhardt, says Sriram Rathi

Sriram Rathi of Anand Rathi suggests holding Wockhardt. "One should wait for any fresh buying because there will be no positive trigger for next two-three quarters," he adds.

Hold Sun Pharma, book profits on Lupin now: AnandRathi

Rathi recommends booking profit in Lupin at current valuations. He has a neutral rating and a ‘hold‘ on the Sun Pharma stock because there are several triggers which can drive the earning surprise positively

See Dr Reddy's FY12 EPS around Rs 80: Anand Rathi

Number 2 drugmaker Dr Reddy's Laboratories Ltd said a US district court has cleared the sale of its generic version of Sanofi-Aventis' allergy treatment drug Allegra D24. Sriram Rathi, Anand Rathi Financial Services says it is definitely a positive news for Dr Reddy’s.